跳至主要内容
临床试验/NCT04278274
NCT04278274招募中不适用

A Post-Neoadjuvant Treatment MRI Based AI System to Predict Pathologic Complete Response for Patients With Rectal Cancer: A Multicenter, Prospective Clinical Study

Sixth Affiliated Hospital, Sun Yat-sen University3 个研究点 分布在 1 个国家目标入组 205 人开始时间: 2020年2月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
205
试验地点
3
主要终点
The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system and expert radiologists in prediction tumor response

研究概览

简要总结

In this study, investigators seek for a better way to identify the potential pathologic complete response (pCR) patients form non-pCR patients with locally advanced rectal cancer (LARC), based on their post-neoadjuvant treatment Magnetic Resonance Imaging (MRI) data.

Previously, a post neoadjuvant treatment MRI based radiomics AI model had been constructed and trained. Here, the predictive power of this artificial intelligence system and expert radiologist to identify pCR patients from non-pCR LARC patients will be compared in this prospective, multicenter, back-to-back clinical study

详细描述

This is a multicenter, prospective, observational clinical study for seeking out a better way to predict the pathologic complete response (pCR) in patients with locally advanced rectal cancer (LARC) based on the post-neoadjuvant treatment Magnetic Resonance Imaging (MRI) data. Patients who have been pathologically diagnosed as rectal adenocarcinoma and defined as clinical II-III stage will be enrolled from the Sixth Affiliated Hospital of Sun Yat-sen University, Sir Run Run Shaw Hospital and the Third Affiliated Hospital of Kunming Medical College. All participants should follow a standard treatment protocol, including neoadjuvant treatment, total mesorectum excision (TME) surgery. Patients with LARC who received neoadjuvant treatment will be enrolled and their post-neoadjuvant treatment MRI images will be used to predict their pathologic response (pCR vs. non-pCR). The artificial intelligence prediction system and the expert radiologist will define the pathologic response as pCR or non-pCR, respectively. The pathologist will provide the final pathology report of TME surgery specimen (pCR or non-pCR) as a standard. The predictive efficacy of these two back-to-back approaches generated will be compared in this multicenter, prospective clinical study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • pathologically diagnosed as rectal adenocarcinoma
  • defined as clinical II-III staging (≥T3, and/or positive nodal status) without distant metastasis
  • receive neoadjuvant chemoradiotherapy or chemotherapy
  • pre- and post-neoadjuvant treatment MRI data obtained
  • receive total mesorectum excision (TME) surgery after neoadjuvant therapy and get the pathologic assessment of tumor response

排除标准

  • with history of other cancer
  • insufficient imaging quality of MRI to delineate tumor volume or obtain measurements (e.g., lack of sequence, motion artifacts)
  • not completing neoadjuvant chemotherapy or chemoradiotherapy
  • tumor recurrence or distant metastasis during neoadjuvant treatment
  • not undergoing surgery resulting in lack of pathologic assessment of tumor response

结局指标

主要结局

The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system and expert radiologists in prediction tumor response

时间窗: baseline

The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system and expert radiologists in identifying the pCR candidates from non-pCR individuals among neoadjuvant chemotherapy or chemoradiotherapy treated LARC patients will be calculated respectively.

次要结局

  • The sensitivity of AI prediction system and expert radiologists in prediction tumor response(baseline)
  • The specificity of AI prediction system and expert radiologists in prediction tumor response(baseline)

研究者

发起方
Sixth Affiliated Hospital, Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

wanxiangbo

professor of Radiation Oncology, Vice Director, Department of Radiation Oncology

Sixth Affiliated Hospital, Sun Yat-sen University

研究点 (3)

Loading locations...

相似试验

Post-Neoadjuvant Treatment MRI Based AI System to... | 临床试验